Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing
Executive Summary
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from FDA's Import Alert
You may also be interested in...
Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with FDA
Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with FDA
As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.